Overview

Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh

Status:
COMPLETED

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Bangladesh

Phase:

PHASE4

Details

Lead Sponsor:

Life for a Child Program, Diabetes Australia

Collaborators:

BADAS-Centre for Health Research and Implementation
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Diabetic Association of Bangladesh (BADAS)

Treatments:

Insulin Glargine